argenex (NASDAQ:ARGX) Issues Earnings Results

argenex (NASDAQ:ARGX) released its quarterly earnings results on Thursday. The company reported $8.02 EPS for the quarter, topping the consensus estimate of $6.05 by $1.97, Zacks reports. argenex had a return on equity of 29.78% and a net margin of 41.58%.

Here are the key takeaways from argenex’s conference call:

• argenx reported positive Phase 3 ADAPT OCULUS results in ocular MG—VYVGART high‑titer met the primary endpoint (p=0.012; mean MG‑II improvement 4.04 vs 1.99) with no new safety signals, and the company plans to file an sBLA.
• Backed by recent seronegative data and a PDUFA date on May 10, management expects to expand VYVGART’s label toward the broadest MG indication, targeting an addressable U.S. population of roughly 60,000 patients.
• Financials were strong—Q4 product sales of $1.3B and full‑year $4.2B (90% YoY growth), first annual operating profit of $1.1B, and ~$4.4B cash at year‑end, which management says funds continued commercial and pipeline investment.
• Commercial momentum continues with ~19,000 patients on VYVGART globally, the prefilled syringe (PFS) launch driving uptake and >4,700 prescribers, and expanded PFS access (UnitedHealthcare) covering >90% of lives to aid adoption in MG and CIDP.
• The pipeline is broadening (next‑gen FcRn assets ARGX‑213/ARGX‑124, empasiprubart MMN readout in Q4, myositis Phase‑3 programs), but management expects higher R&D and SG&A spending in 2026—continued investment with timing and commercial impact still uncertain.

argenex Price Performance

Shares of NASDAQ ARGX traded down $45.42 during trading on Thursday, hitting $771.53. 829,988 shares of the company were exchanged, compared to its average volume of 394,033. argenex has a 1 year low of $510.05 and a 1 year high of $934.62. The company has a market cap of $47.74 billion, a price-to-earnings ratio of 33.13, a PEG ratio of 0.73 and a beta of 0.37. The firm’s fifty day moving average price is $829.64 and its 200 day moving average price is $810.13.

Key Headlines Impacting argenex

Here are the key news stories impacting argenex this week:

• Positive Sentiment: Positive Phase‑3 result: argenx reported topline positive ADAPT OCULUS data for VYVGART in ocular myasthenia gravis (primary endpoint met, p=0.012), supporting a planned sBLA to the FDA to expand the label into oMG. Argenx Touts Positive Phase 3 Eye Disease Study Results
• Positive Sentiment: Strong sales and FY results: argenx announced $1.3B Q4 and $4.2B FY 2025 product net sales (≈90% YoY growth) — evidence of rapid commercial traction for VYVGART. Full Year 2025 Financial Results
• Positive Sentiment: Quarterly beat: ARGX reported $8.02 EPS for the quarter vs. $6.05 consensus, with strong margins and ROE — a near-term fundamental beat that underpins revenue strength. Conference call and slide deck available for details. Earnings Release & Call Materials
• Neutral Sentiment: Analyst notes and previews: several earnings previews and insights were published ahead of/with results — useful for forward‑looking assumptions but do not change the headline clinical and sales news. Earnings Insights
• Negative Sentiment: Heavy trading and profit‑taking pressure: intraday volume is well above average and the stock is trading lower — likely a sell-the-news response after a large run and the strong prints. Market is also digesting valuation (large market cap, elevated multiples) versus near-term visibility on incremental label expansion and global uptake. Market Data
• Negative Sentiment: Short‑interest data appears unreliable in some reports (zero/NaN entries) — but elevated volatility and higher volume can attract short sellers or traders, adding near‑term pressure. Monitor confirmed short interest updates. What To Expect From Q4 2025

Wall Street Analysts Forecast Growth

A number of equities research analysts have issued reports on ARGX shares. Truist Financial increased their price target on argenex from $950.00 to $1,030.00 and gave the company a “buy” rating in a research report on Thursday, January 8th. Royal Bank Of Canada raised their target price on shares of argenex from $860.00 to $925.00 and gave the company an “outperform” rating in a report on Wednesday, December 17th. Wedbush reiterated an “outperform” rating and set a $1,000.00 price target on shares of argenex in a report on Wednesday, January 14th. TD Cowen lifted their price objective on shares of argenex from $800.00 to $1,146.00 and gave the stock a “buy” rating in a research report on Friday, October 31st. Finally, Citigroup dropped their price objective on argenex from $1,124.00 to $1,091.00 and set a “buy” rating on the stock in a report on Thursday, January 8th. One investment analyst has rated the stock with a Strong Buy rating, eighteen have issued a Buy rating and five have given a Hold rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $986.78.

Institutional Investors Weigh In On argenex

A number of hedge funds and other institutional investors have recently modified their holdings of the stock. Wellington Management Group LLP grew its holdings in shares of argenex by 80.1% in the 3rd quarter. Wellington Management Group LLP now owns 729,986 shares of the company’s stock worth $538,408,000 after acquiring an additional 324,653 shares during the period. Morgan Stanley grew its holdings in argenex by 19.2% in the fourth quarter. Morgan Stanley now owns 518,852 shares of the company’s stock valued at $436,331,000 after purchasing an additional 83,746 shares during the last quarter. Invesco Ltd. increased its position in shares of argenex by 390.4% in the fourth quarter. Invesco Ltd. now owns 416,408 shares of the company’s stock valued at $350,178,000 after buying an additional 331,489 shares in the last quarter. Bank of America Corp DE increased its position in shares of argenex by 1.9% in the third quarter. Bank of America Corp DE now owns 342,379 shares of the company’s stock valued at $252,525,000 after buying an additional 6,259 shares in the last quarter. Finally, Two Sigma Investments LP raised its stake in shares of argenex by 570.3% during the 3rd quarter. Two Sigma Investments LP now owns 294,160 shares of the company’s stock worth $216,961,000 after buying an additional 250,278 shares during the last quarter. 60.32% of the stock is currently owned by institutional investors and hedge funds.

About argenex

argenx (NASDAQ: ARGX) is a biotechnology company focused on the discovery, development and commercialization of antibody-based therapeutics for severe autoimmune and neuromuscular diseases. The company uses its proprietary SIMPLE Antibody platform to generate differentiated antibodies and engineered Fc regions, and it pursues mechanisms that modulate the neonatal Fc receptor (FcRn) to reduce pathogenic IgG levels. Argenx’s research and development activities span target identification, preclinical development and late-stage clinical programs aimed at addressing unmet needs in immunology.

The company’s lead product, efgartigimod (marketed as Vyvgart), is an FcRn antagonist developed to reduce circulating IgG antibodies and treat IgG-mediated disorders.